abiraterone in high and low risk, hormone sensitive metastatic prostate cancer
Published 2 years ago • 1.2K plays • Length 4:10Download video MP4
Download video MP3
Similar videos
-
2:12
abiraterone for metastatic, hormone sensitive, prostate cancer
-
2:05
abiraterone in metastatic castration-sensitive prostate cancer
-
1:08
dr. graff on the use of abiraterone in metastatic prostate cancer
-
1:17
abiraterone for the treatment of cn1 prostate cancer
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
8:56
abiraterone in metastatic prostate cancer
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
2:06
dr. chi on androgen deprivation therapy for high-risk metastatic hormone-naive prostate cancer
-
1:38
5-year follow up of short-course abiraterone and adt for high-risk prostate cancer
-
1:11
dr. burgess on the synergy between abiraterone and adt in prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
13:09
pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
0:46
who should get abiraterone in non-metastatic prostate cancer?
-
25:31
management of advanced hormone-sensitive and castration-resistant prostate cancer
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
16:26
patient selection in metastatic hormone-sensitive prostate cancer (mhspc)